Article
Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer.
Nature communications - 29 Nov 2016
Henzler Christine, Li Yingming, Yang Rendong, McBride Terri, Ho Yeung, Sprenger Cynthia, Liu Gang, Coleman Ilsa, Lakely Bryce, Li Rui, Ma Shihong, Landman Sean R, Kumar Vipin, Hwang Tae Hyun, Raj Ganesh V, Higano Celestia S, Morrissey Colm, Nelson Peter S, Plymate Stephen R, Dehm Scott M
Abstract excerpt
Molecularly targeted therapies for advanced prostate cancer include castration modalities that suppress ligand-dependent transcriptional activity of the androgen receptor (AR). However, persistent AR signalling undermines therapeutic efficacy and promotes progression to lethal castration-resistant prostate cancer (CRPC), even when patients are treated with potent second-generation AR-targeted therapies...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.